Realistic timeline · weeks 1–12
Not a clinical abstract, and not a sales page. This is what to expect from us, and what to expect from your body — written for women over 40 in perimenopause and beyond. Week by week, in plain language, with the signals worth tracking, the normal-vs-flag thresholds, and how to read your own symptom changes against the hormonal shifts already underway.
Week 1–2
Onboarding
The first two weeks are about setup, not effect. Your intake has been reviewed, your approach stack and dose ranges have been set against your cycle phase and hormonal baseline, and your first dose map — the injection schedule you'll keep through the first month — has been written down. The product has arrived. You have a single curator who already knows your biology.
During this window there is typically nothing in particular to feel. Peptides are not a stimulant and they are not a sedative. Most women on a CJC-1295 or BPC-157 stacked approach will not notice a perceptible signal in week one or two. If you do, it is most often a subtle improvement in post-exertion recovery time rather than a sudden change in energy, mood, or sleep.
Already have questions? Read The Midlife Questions Worth Asking →Week 3–4
Earliest perceptible signals
By week three or four, the smallest perceptible signals begin to appear. On a CJC-1295-led stack, the most common first observation is a reduction in sleep latency — falling asleep takes ten to twenty minutes less than baseline — or a small improvement in the perceived depth of slow-wave sleep. On a BPC-157-led stack, transient injection-site sensitivity and the return of easeful recovery from a familiar training load is the more common first signal.
None of these are large effects. They are small, repeatable, and worth recording — not because they prove the approach is "working," but because they offer the first baseline comparison point against which week 5–6 changes can be read. It is normal for the first few weeks to feel more like a quiet settling than a turn.
Common onboarding questions →Week 5–6
First reading-against-baseline moment
Week five and six are the first true reading-against-baseline window in the cycle. The signals you recorded in weeks three and four now become the comparison set. On BPC-157, you can ask whether the post-exertion recovery interval has actually shortened. On CJC-1295, whether sleep architecture — not just latency — has changed. On KLOW, whether inflammation and tissue recovery are tracking together rather than separately.
Most of what you'll observe in this window is normal. Mild injection-site sensitivity, a transient headache in the first week of CJC-1295 in some women, and a few days of mood lability as the hormone-entrained system re-settles are all within range. What is not within range — and what should prompt a check-in with your curator — is in the flag grid below.
Why time-to-effect differs across approaches →Week 7–8
First compounding check
For women on the KLOW quad-peptide complex, the eight-week point is the end of the first full ON cycle. The expected pattern at this point is a discernible difference between weeks one–two and weeks seven–eight across the dimensions your curator has been tracking with you — typically a tighter recovery curve, a clearer sleep architecture, and a calmer inflammatory baseline across the cycle. The two-week OFF cycle that follows is part of the approach and is not a withdrawal.
For women on core single-or-double-peptide stacks (Recovery, Sleep, Longevity), week seven and eight are where compounding first becomes readable against the week-three–four baseline. Coordinated with cycle phase, this is also the moment where some women first notice a softer premenstrual window or a more even-tempered luteal phase — not because the peptides replace hormones, but because receptor sensitivity has shifted in a useful direction.
Read the KLOW cycle structure →Week 9–12
Month-3 review window
The month-3 marker is a real clinical touchpoint, not a marketing milestone. Your curator reviews what you've reported — the recovery intervals, sleep latency changes, cycle phase observations, and any flag events — and decides whether to continue as-is, adjust dose or timing, layer in a complementary peptide, or hold the approach stable while a hormonal baseline shifts underneath it.
This is also where the same question gets asked at month 6, and then again at every phase transition thereafter. For women in perimenopause, the approach reads cycle phase as a moving input and adjusts against it. For women who have crossed into menopause or postmenopause, the approach locks in differently — with the month-3 review reading more against inflammatory baseline and metabolic markers than against cycle phase.
What happens at month 3 and month 6? See the FAQ →Observation, not measurement
We are not asking you to build a self-tracker. The point is observation in plain language, captured well enough that you and your curator can read it together at the month-3 review. If you can answer these six questions in a sentence each, you have what the review needs.
Six signals to record across the cycle
Thresholds
Most of what you'll notice in the first ninety days is normal adaptation. Some small number of observations are worth raising at the next curator check-in. The grid below is the working heuristic your curator uses — if your situation matches the right column, write to us rather than waiting.
Normal first-90-days observations
Worth flagging at the next check-in
Hormonal baseline vs approach signal
Perimenopause is a 10–15 year transition. Estrogen and progesterone fluctuate unpredictably before settling into a lower baseline. Some symptoms you'd otherwise attribute to a working approach — softer sleep latency, a tighter recovery curve, a calmer luteal phase — can also be reading a hormonal shift that has nothing to do with the approach itself.
The month-3 review is built specifically to disentangle the two. A signal that appeared in week one, persisted, and is now stronger by week eight is a different story from the same signal appearing and disappearing in phase with the cycle. Both are real — only one is an approach effect, and the curator's job is to read which one. The longer arc that follows — what reads well at 6, 12, and 24 months, and which biomarkers are worth tracking through those windows — is the multi-year framing — the early-window sleep-architecture baseline is most often the first driver the 90-day review surfaces, and you can trace it on Sleep & Stress Adjuncts →; the multi-year framing itself reads on Longitudinal Outcomes →.
See the phase map — Early, Late, Post →Continue learning
Hand-picked reads that follow from this page — not an algorithmic suggestion.
Consultation guide
A walkthrough of the four-group intake — cycle phase, symptoms, hormonal history, and goals — and how those answers map to an approach recommendation.
Read →Continuity across stages
How a single record carries your approach through perimenopause into menopause and post-menopause without restart.
Read →Female physiology
The four axes of sex difference that make a male-derived baseline the wrong place to start for women 40+.
Read →Common starting points
If you’re not sure this page matched what you’re feeling this week, the symptom-first entry at /start-here is where most readers place themselves first.
Sleep
If sleep is the dominant thing you’re tracking in your first ninety days, lead with the symptom card before the approach.
Start there →Cognition
Cognition drift and slow-wave-sleep stack — if focus is the dominant change, start with the cognition card.
Start there →Bone
Bone is the dominant postmenopausal readout; if you’re past the transition, lead with the bone card.
Start there →